Myotonic Dystrophy clinical trials

Explore recruiting myotonic dystrophy clinical trials.

Recruiting myotonic dystrophy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Myotonic Dystrophy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects with Myotonic Dystrophy Type I

Netherlands, France, Italy, Spain, Germany, Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2, Randomized, Double-blind, Placebo‑controlled Single- and Multiple‑dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX‑670 in Adult Subjects with Myotonic Dystrophy Type 1

Netherlands, Spain, Belgium, France, Germany, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR compared to Mexiletine IR in Patients with Non-Dystrophic Myotonias (ACHILLES study)

Germany, Italy, Belgium, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients with Myotonic Dystrophy Type 1 and Type 2 who have completed the MEX-DM-302 Study.

Belgium, Italy, Germany, Denmark, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1

Netherlands, France, Italy, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of Intravenous Administration of ATX-01 In Male and Female Participants aged 18 to 64 with Classic Myotonic Dystrophy Type 1 (DM1)

Italy, France, Spain, Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Myotonic Dystrophy trials by city

Myotonic Dystrophy in Toronto Myotonic Dystrophy in Vancouver Myotonic Dystrophy in Montreal Myotonic Dystrophy in Calgary Myotonic Dystrophy in Edmonton Myotonic Dystrophy in Ottawa Myotonic Dystrophy in Winnipeg Myotonic Dystrophy in Quebec City Myotonic Dystrophy in Hamilton Myotonic Dystrophy in Kitchener Myotonic Dystrophy in London Myotonic Dystrophy in Halifax Myotonic Dystrophy in New York Myotonic Dystrophy in Los Angeles Myotonic Dystrophy in Chicago Myotonic Dystrophy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease